Inclusion Criteria:

- Age > 18 years old

- Zubrod Performance Status 0 or 1

- Adequate bone marrow, liver and renal function as assessed by the following:

- Hemoglobin > 9.0 g/dl

- Absolute neutrophil count (ANC) > 1,500/mm3

- Platelet count > 100,000/mm3

- Total bilirubin < 1.5 times institutional upper limit of normal (ULN)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 times
the institutional ULN

- Creatinine < 1.5 times institutional ULN

- Histologically or cytologically confirmed renal cell carcinoma, which is metastatic,
unresectable or recurrent.

- Life expectancy > 6 months

- Local recurrence or progression of primary lesion or progression, or symptomatic
progression in extra-cranial, extra-pulmonary metastases while on sorafenib

- Measurable disease

- Bone metastases must have a tissue component measurable by imaging.

- No untreated brain metastases

- Resolution of pre-existing toxicity from prior therapy excluding alopecia and taste
alteration.

- Willingness and ability to comply with continuing sorafenib, visits, treatment plans,
laboratory tests and study procedures.

- All treated lesions must comply with SBRT dose constraints

- More than 28 days since any prior systemic or local therapy for this cancer,
including investigational agents and surgical procedures exclusive of sorafenib

- Women of childbearing potential and men must agree to use adequate contraception
(barrier method of birth control)

- Women of childbearing potential must have a negative serum pregnancy test performed
within 7 days prior to the start of treatment.

- Ability to understand and the willingness to sign a written informed consent.

- Prothrombin time(PT) and partial thromboplastin time (PTT) within normal limits.

Exclusion Criteria:

- Lesion in remaining (solo) kidney

- Contraindications to radiotherapy or prior radiotherapy overlapping current site(s)
of disease.

- Cardiac disease: Congestive heart failure. Patients must not have unstable angina
(anginal symptoms at rest) or new onset angina (began within the last 3 months) or
myocardial infarction within the past 6 months.

- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.

- Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic
pressure > 90 mmHg, despite optimal medical management.

- Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.

- Active clinically serious infection

- Thrombolic or embolic events such as a cerebrovascular accident including transient
ischemic attacks within the past 6 months.

- Pulmonary hemorrhage/bleeding event within 4 weeks of first dose of study drug.

- Any other hemorrhage/bleeding event within 4 weeks of first dose of study drug.

- Serious non-healing wound, ulcer, or bone fracture.

- Evidence or history of bleeding problems

- Major surgery, open biopsy or significant traumatic injury within 4 weeks of first
study drug.

- Use of St. John's Wort or rifampin (rifampicin).

- Known or suspected allergy to sorafenib or any agent given in the course of this
trial.

- Any condition that impairs patient's ability to swallow whole pills.

- Any malabsorption problem.